ReviewNeurology and therapy2019
Therapy of Sialorrhea with Botulinum Neurotoxin.
Review in Neurology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force.Clinical and experimental otorhinolaryngology · 2023Guideline
- Oral health effects of botulinum toxin treatment for drooling: a systematic review.Medicina oral, patologia oral y cirugia bucal · 2021Pooled it
- Holistic management of epilepsy in adults with intellectual development disorders.Epileptic disorders : international epilepsy journal with videotape · 2026Article
- Orofacial dysfunction in persons with congenital or childhood-onset neuromuscular disorders.Journal of neuromuscular diseases · 2026Article
- Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.Acta neurologica Belgica · 2026Review
- Dysphagia After Cosmetic Submandibular Gland Botulinum Neurotoxin Type A Injection: A Case Report.Healthcare (Basel, Switzerland) · 2026Article
- Posterior drooling and saliva aspiration in children with cerebral palsy: hidden threats.World journal of pediatrics : WJP · 2025Review
- Saliva as a Diagnostic Tool for Systemic Diseases-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Rethinking ALS: Current understanding and emerging therapeutic strategies.AIMS neuroscience · 2025Review
- Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review.Cureus · 2024Review
- Therapy with botulinum neurotoxin for Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Observational
- Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins · 2024Review
- The effectiveness of ultrasound-guided injection of BTX-A in the management of sialorrhea in neurogenic dysphagia patients.Laryngoscope investigative otolaryngology · 2023Article
- Botulinum toxin in the treatment of sialorrhea in severe neurological patients with tracheotomy.Brain and behavior · 2023Article
- Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease.Clinical parkinsonism & related disorders · 2023Review
- Botox injection in treatment of sialorrhea in children with cerebral palsy.American journal of neurodegenerative disease · 2023Article
- Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.Therapeutic advances in psychopharmacology · 2023Review
- Review
- Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.Toxins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin (BoNT) is considered the treatment of choice for various symptoms and diseases such as focal dystonia and focal spasticity. The effects of BoNT on the salivary glands have also been known for years, but their use was limited because of a lack of approval studies. Now the indication of sialorrhea is approved in some countries for incobotulinumtoxinA, such as the USA and Europe, and therapy could also become the treatment of choice. According to the pivotal study, a dose of 100 units of incobotulinumtoxinA, which is divided into the parotid and submandibular glands, is recommended. RimabotulinumtoxinB is approved in the USA only. To define the value of this therapy, we must consider anatomy, physiology, and available therapies. Therapy includes conservative measures such as functional dysphagia therapy, oral or transdermal application of anticholinergics, and, in selected cases, radiotherapy and surgical procedures. A combination of different approaches is optional. On the basis of the evidence and clinical experience, BoNT injections will be the first line of pharmacotherapy for chronic sialorrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.